206 related articles for article (PubMed ID: 29609753)
1. Treating Dyslipidemia in Type 2 Diabetes.
Nelson AJ; Nicholls SJ
Cardiol Clin; 2018 May; 36(2):233-239. PubMed ID: 29609753
[TBL] [Abstract][Full Text] [Related]
2. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
Karalis DG
Clin Cardiol; 2008 Jun; 31(6):241-8. PubMed ID: 17847038
[TBL] [Abstract][Full Text] [Related]
3. Combination lipid therapy in type 2 diabetes mellitus.
Vergès B
Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502
[TBL] [Abstract][Full Text] [Related]
4. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
Zhang J; Rocha NA; McCullough PA
Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
[TBL] [Abstract][Full Text] [Related]
5. Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome.
Robins SJ
Curr Cardiol Rep; 2005 Nov; 7(6):457-64. PubMed ID: 16256016
[TBL] [Abstract][Full Text] [Related]
6. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
8. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials.
Farmer JA
Curr Atheroscler Rep; 2007 Aug; 9(2):162-8. PubMed ID: 17877926
[TBL] [Abstract][Full Text] [Related]
9. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
10. Lipid control in patients with diabetes mellitus.
Betteridge DJ
Nat Rev Cardiol; 2011 May; 8(5):278-90. PubMed ID: 21403658
[TBL] [Abstract][Full Text] [Related]
11. Clinical controversies in lipid management.
Tziomalos K
Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
[TBL] [Abstract][Full Text] [Related]
12. Management of non-high-density lipoprotein abnormalities.
Rosenson RS
Atherosclerosis; 2009 Dec; 207(2):328-35. PubMed ID: 19545870
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart.
Katsiki N; Tentolouris N; Mikhailidis DP
Curr Opin Cardiol; 2017 Jul; 32(4):422-429. PubMed ID: 28362666
[TBL] [Abstract][Full Text] [Related]
14. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.
Sacks FM; Hermans MP; Fioretto P; Valensi P; Davis T; Horton E; Wanner C; Al-Rubeaan K; Aronson R; Barzon I; Bishop L; Bonora E; Bunnag P; Chuang LM; Deerochanawong C; Goldenberg R; Harshfield B; Hernández C; Herzlinger-Botein S; Itoh H; Jia W; Jiang YD; Kadowaki T; Laranjo N; Leiter L; Miwa T; Odawara M; Ohashi K; Ohno A; Pan C; Pan J; Pedro-Botet J; Reiner Z; Rotella CM; Simo R; Tanaka M; Tedeschi-Reiner E; Twum-Barima D; Zoppini G; Carey VJ
Circulation; 2014 Mar; 129(9):999-1008. PubMed ID: 24352521
[TBL] [Abstract][Full Text] [Related]
15. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
Gonna H; Ray KK
Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():6-16. PubMed ID: 31002453
[TBL] [Abstract][Full Text] [Related]
16. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Campbell J; Mohiuddin SM
Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
[TBL] [Abstract][Full Text] [Related]
17. New frontiers in the treatment of diabetic dyslipidemia.
Wang SY; Hsieh MC; Tu ST; Chuang CS
Rev Diabet Stud; 2013; 10(2-3):204-12. PubMed ID: 24380093
[TBL] [Abstract][Full Text] [Related]
18. [What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
Rosolová H
Vnitr Lek; 2015 Nov; 61(11):971-5. PubMed ID: 26652786
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
20. Treatment of dyslipidemia in patients with type 2 diabetes.
Vijayaraghavan K
Lipids Health Dis; 2010 Dec; 9():144. PubMed ID: 21172030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
